Centers | ||
FDA Oncology Center of Excellence Project Catalyst | Therapeutic Accelerator Program (TAP) | EU-OPENSCREEN |
Providing a regulatory platform to connect scientific knowledge, creative insight, and medical professionals to foster early-stage product innovation |
Test |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Partnerships |
Events |
Jobs |
UCB Partners with Oxford UniversityUCB has entered into a research and development partnership with Oxford University in Neurology and Immunology areas. UCB will provide 3.6 million pounds to Oxford scientists over a period of three year to conduct research. View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Sanofi and Weill Cornell Medical College to Discover New Drus to Treat TuberculosisSanofi has entered into a new collaboration with Dr.Carl Nathan's laboratory at Weill Cornell Medical College to screen existing compounds and develop new compounds to shorten the course of treatment of tuberculosis and increase effectiveness of... View all |
No EVENTS for listing |
No Job Posts |


